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Clinaﬂoxacin is a broad-spectrum ﬂuoroquinolone that was originally developed and
subsequently abandoned in the late 1990s as a human health antibiotic for respiratory
diseases. The purpose of this study was to investigate the activity of clinaﬂoxacin as
a possible treatment for respiratory disease in cattle and pigs. Minimum inhibitory
concentration (MIC) values were determined using Clinical and Laboratory Standards
Institute recommended procedures with recent strains from the Zoetis culture collection.
Rodent efﬁcacy was determined in CD-1 mice infected systemically or intranasally
with bovine Mannheimia haemolytica or Pasteurella multocida, or swine Actinobacillus
pleuropneumoniae, and administered clinaﬂoxacin for determination of ED50 (efﬁca-
cious dose-50%) values. The MIC90 values for clinaﬂoxacin against bovine P. multocida,
M. haemolytica, Histophilus somni, and M. bovis were 0.125, 0.5, 0.125, and 1 μg/ml,
respectively, and the MIC90 values against swine P. multocida, A. pleuropneumoniae,
S. suis, andM. hyopneumoniae were≤0.03, ≤0.03, 0.125, and≤0.008μg/ml, respectively.
Efﬁcacy in mouse models showed average ED50 values of 0.019 mg/kg/dose in the
bovine M. haemolytica systemic infection model, 0.55 mg/kg in the bovine P. multocida
intranasal lung challenge model, 0.08 mg/kg/dose in the bovine P. multocida systemic
infection model, and 0.7 mg/kg/dose in the swine A. pleuropneumoniae systemic infection
model. Clinaﬂoxacin shows good in vitro activity and efﬁcacy in mouse models and
may be a novel treatment alternative for the treatment of respiratory disease in cattle
and pigs.
Keywords: clinafloxacin, respiratory diseases, minimum inhibitory concentration, efficacy, mouse models,
veterinary medicine
INTRODUCTION
Respiratory disease in cattle and pigs is one of the most economi-
cally important diseases of the feedlot industry with global losses
estimated to be over $3 billion per year (Watts and Sweeney, 2010).
Respiratory disease in these livestock animals is a multi-factorial
and multi-agent disease. Transportation over long distances, often
associated with exhaustion, starvation, dehydration, chilling, or
overheating depending onweather conditions, dusty environmen-
tal conditions in the feedlot, and nutritional stress associated with
changes in the diet all serve as stressors leading to “shipping fever”
(http://www.merckvetmanual.com/mvm/index.jsp?cﬁle=htm/bc/
121208.htm). Additionally, viral infections are important eti-
ological agents for subsequent bacterial infections in which
Mannheimia haemolytica,Pasteurellamultocida,Histophilus somni,
and Actinobacillus pleuropneumoniae are the most important
pathogens (Watts and Sweeney, 2010). The ﬂuoroquinolone
antimicrobial agents danoﬂoxacin, enroﬂoxacin, and mar-
boﬂoxacin are currently approved for the treatment of bovine
respiratory disease (BRD) and swine respiratory disease (SRD)
caused by these bacterial pathogens. There may be a need for
newer antimicrobial agents with uniquemechanisms of action due
to continued emergence of bacterial resistance to danoﬂoxacin,
enroﬂoxacin, and marboﬂoxacin by these pathogens (Watts and
Sweeney, 2010).
Clinaﬂoxacin was ﬁrst introduced into the literature in 1991
and was reported to have excellent broad in vitro activity against
medically signiﬁcant bacteria (Cohen et al., 1991). This com-
pound was developed as a human health agent for the treatment
of bacterial pneumonia but subsequently abandoned due to spe-
ciﬁc adverse events related to hypoglycemia and photosensitivity
(Siami et al., 2002; Chow, 2003). Due to the extensive toxicologi-
cal safety package, this compound was re-evaluated as an animal
health antimicrobial agent for the treatment of bacterial infections
that cause respiratory disease in cattle andpigs. The purpose of this
study was to determine the in vitro activity and rodent efﬁcacy of
clinaﬂoxacin when tested against pathogens associated with BRD
and SRD.
MATERIALS AND METHODS
BACTERIAL STRAINS
Bacterial strains frombovine and swine respiratory infectionswere
used in the present study and came from the Zoetis surveillance
program isolated from clinical cases of BRD and SRD. Bovine iso-
lates used in the studies (P. multocida, M. haemolytica, H. somni)
were part of the 2008 Zoetis surveillance program and swine iso-
lates (P. multocida, A. pleuropneumoniae, S. suis) were part of
the 2009 surveillance program. Additionally, mycoplasmas were
recovered from tulathromycin clinical trials from 2008 to 2010.
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All isolates were identiﬁed by clinical diagnostic laboratories using
biochemical methods. The isolates were frozen in trypticase soy
broth containing 10% glycerol and maintained at −70◦C as part
of the Zoetis culture collection. Isolates were plated and grown on
trypticase soy agar plates containing 5% sheep blood. The quality
control strains Staphylococcus aureus ATCC 29213, Enterococcus
faecalis ATCC 29212, Escherichia coli ATCC 25922, Streptococcus
pneumoniae ATCC 49619, and Mannheimia haemolytica ATCC
33396 were originally acquired from the American Type Culture
Collection (Manassas, VA, USA).
ANTIMICROBIAL AGENTS
The antibiotic powders used in the experiments were obtained
from the indicated sources: danoﬂoxacin, enroﬂoxacin (Riedel-de
Haen); clinaﬂoxacin, ceftiofur (Zoetis).
ANTIMICROBIAL SUSCEPTIBILITY TESTING
Cation-adjusted Müller-Hinton broth (MHB; Difco Laboratories,
Detroit,MI,USA)wasused for susceptibility testingof P.multocida
and M. haemolytica. Cation-adjusted MHB supplemented with
2.5% lysed horse blood was used for susceptibility testing of S. suis.
Veterinary fastidious medium (VFM) broth (TREK Diagnostic
Systems) was used for susceptibility testing of A. pleuropneu-
moniae and H. somni. The minimum inhibitory concentration
(MIC) values were determined using the broth microdilution pro-
tocol according to the standards of the [Clinical and Laboratory
Standards Institute (CLSI),2008]. TheMICwas the lowest concen-
tration of drug which prevented macroscopically visible growth
under the conditions of the test. Assay control was monitored
with ATCC quality control strains. MICs were done in duplicate
on two separate days. When MICs for all compounds tested were
within one doubling dilution, the original results were used for
analysis and reporting. On those occasions where results differed
by more than one doubling dilution, the isolate was tested a third
time and those results were used for analysis unless the results were
inconsistent with either of the previous two sets of MIC results.
When an isolate tested differently all three times it was determined
to be too inconsistent in testing to be included in the analysis. In
those rare instances, a new bacterial isolate was selected for MIC
testing. Determination of MICs against all mycoplasma isolates
were conducted at Microbial Research, Inc. (MRI) in Fort Collins,
CO, USA. There is no standardized procedure for the suscepti-
bility testing of veterinary Mycoplasma listed in CLSI document
M31-A3 (CLSI, 2008). MIC plates were prepared by MRI using
Modiﬁed Hayﬂick’s broth with alamarBlue for isolates except M.
hyopneumoniae which required Friis broth. Each well contained
50 μl of the appropriate diluted drug prepared at 2× the ﬁnal
concentration and each well was inoculated with 50 μl of each
isolate. Plates were incubated aerobically at 36◦C for 16–24 h (M.
bovis and bovirhinis) and 2–14 days (M. hyopneumoniae). There
are no published quality control ranges available for the testing
of Mycoplasma species, however, M. hyopneumoniae ATCC 25934
was included as part of the test isolates. Positive growth control
wells for each tested isolate were monitored and sterility checks of
plates by sterile diluent inoculation of the negative control well was
performed. MIC results were the lowest concentration of antimi-
crobial agent that completely inhibited growth of the organism
as detected by color change of the broth when color change was
noted in the positive control well.
TIME-KILL ASSAYS
The bactericidal effects of clinaﬂoxacin and comparator ﬂuoro-
quinolones against 10 bacterial isolates were assessed by a time-kill
assay. For M. haemolytica and P. multocida, cultures were grown
overnight at 35◦C on Müller-Hinton agar and for H. somni and
A. pleuropneumoniae cultures were grown on chocolate Müller-
Hinton agar. Assay tubes were prepared to contain 8.5 ml of the
appropriate medium (cation-adjusted MHB for M. haemolytica
andP.multocida, andVFMforH. somni andA. pleuropneumoniae),
0.5 ml of the antibacterial agent, and 1.0 ml of the McFarland-
equivalent culture in appropriate medium which resulted in a cell
concentration of approximately 107 CFU/ml for most cultures.
The ﬁnal drug concentrations tested were 1× and 4× the MIC for
each test strain. An identical assay tube that contained broth and
inoculum, but no antibacterial agent, served as the culture growth
control. The assay tubes were incubated at 35◦C and samples were
removed for viable counts at 0, 2, 6, and 24 h for all cultures. A
100-μl sample was removed from the assay tube at each timepoint
and serial dilutions (10−1 to 10−8) were prepared in appropriate
media. A 100-μl volume of each dilution was applied to dupli-
cate blood agar plates (BAPs), spread evenly over the plate surface,
and incubated overnight at 35◦C with or without CO2. Colonies
were manually counted and plates at a dilution yielding a count of
20–200 were utilized.
MPC DETERMINATIONS
Methods for mutant prevention concentrations (MPCs) were
determined following the method of Blondeau et al. (2001).
Brieﬂy, two bacterial strains, S. suis and P. multocida from SRD
and BRD, respectively, were selected for testing and subcultured to
multiple agar plates (ﬁve each) and incubated for 18–24 h under
proper incubating conditions for the microorganisms. The con-
tents of the inoculated agar plates were removed with a sterile
swab and transferred to cation-adjusted MHB or cation-adjusted
MHB containing 2.5% lysed horse blood (250 ml). The inocu-
lated broth was incubated for 18–24 h under proper incubating
conditions. Broth cultures were centrifuged and the pellet resus-
pended in a lower volume of fresh broth media. Once the bacterial
density was adjusted, ≥109 CFUs were inoculated to agar plates
containing clinaﬂoxacin, danoﬂoxacin, or enroﬂoxacin at twofold
concentrations ranging from 256 to 0.007 μg/ml and incubated
under ambient conditions at 35◦C. Cultures were read at 24 and
48 h and the lowest drug concentration that prevented growth
was determined as the MPC. Based on parent MIC, an MPC/MIC
ratio was determined for evaluation. Data for time-kill and MPC
analyses were collected once and results were consistent with data
from previous journal reports.
MOUSE EFFICACY ASSAYS
Female CD-1 mice were acquired from Charles River Labs
(Portage, MI, USA) at a weight of 13–14 g, and acclimated for 3–6
days. Mice were randomized when delivered on-site and housed
10/large shoebox cage, on litter with nestlets for environmental
enrichment. On Study Day 1, approximately 10% of the mice
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were weighed to provide an average weight for calculation of
drug concentrations to be administered. On Study Day 0, all mice
received a challenge inoculation (induced infection). Compounds
tested included clinaﬂoxacin, enroﬂoxacin, and ceftiofur. All mice
received one to three subcutaneous (SC) injections of stated com-
pounds starting at 1 or 18 h post-challenge (PC) depending on the
model. SC injections were administered in the left and/or right
inguinal region, using a 28 gage X½ inch insulin needle-syringe
to deliver 0.1 ml per injection. Serial two- or threefold dilutions
of test compounds were dosed to different groups of mice, and
mice were monitored for 6 or 8 days. Efﬁcacy of test compounds
was calculated as ED50 values (efﬁcacious dose-50%) by use of
GraphPad Prism. All animal studies were conducted under the
guidelines, and with the approval of, the Pﬁzer Animal Health
Institutional Animal Care and Use Committee.
For the Mannheimia haemolytica systemic infection model, 25
colonies from overnight growth on BAP were aseptically picked
and inoculated into 50 ml of room temperature brain-heart infu-
sion broth (BHIB; BBLTM, Becton, Dickinson and Company) and
placed at 35–37◦C for 3.5–4 h of incubation. Appropriate dilu-
tions in cold BHIB with 4% brewer’s yeast were made to achieve
∼2.5 × 108 CFU/ml. A volume of 0.2 ml of this adjusted chal-
lenge material was administered to mice by the intraperitoneal
(IP) route using a 25 gage X 5/8 inch needle on a 1-ml tuberculin
syringe. Placement of the IP challenge was in the mouse’s lower
right abdominal quadrant. Drugs were administered via SC injec-
tion as described above at either 1 and 3 h PC or at 1, 24, and 48 h
PC. Mice were monitored for 6 days.
For the Pasteurella multocida intranasal (IN) infection model,
ﬁve colonies from the overnight growth on BAP were picked and
inoculated into 10 ml of room temperature BHIB. Appropriate
dilutions in cold BHIBweremade to achieve∼1.25× 105 CFU/ml.
Mice were anesthetized either by an IP injection of 100 mg/kg
ketamine + 10 mg/kg xylazine, or by isoﬂurane inhalation via
the Compac 5 Anesthesia Center. A volume of 0.04 ml (40 μl) of
the adjusted challenge material was slowly applied to the nares
of anesthetized mice, using a Rainin L100 Pipet Lite manual
pipettor with sterile tips. At 18 h PC, mice received one SC
injection of 0.1 ml of appropriate dilutions of drug prepared
in phosphate buffered saline (PBS). Mice were monitored for
8 days.
For the Pasteurella multocida systemic infection model, dilu-
tions in cold PBS were made to achieve ∼1.5 × 104 CFU/ml. A
volume of 0.1 ml of this adjusted challenge material was adminis-
tered to mice by the IP route as described above. Drugs to be tested
were administered via SC injection as described above at 1 and 3 h
PC. Mice were monitored for 6 days.
For the A. pleuropneumoniae systemic infection model, fresh
supplement C at 2% concentration was added to 30 ml of room
temperature BHIB. Fifteen A. pleuropneumoniae colonies were
transferred to the BHIB with supplement C, then incubated for
∼4 h until the A600 of undiluted growth approximated a pre-
determined optical density known to yield ∼2 × 108 CFU/ml.
Micewere challengedwith a volumeof 0.2ml/mouse, by IP admin-
istration, as described above. Drugs to be tested were administered
via SC injection as described above at 1, 24, and 48 h PC. Mice
were monitored for 6 days.
RESULTS
ANTIMICROBIAL SUSCEPTIBILITY TESTING
The MICs of clinaﬂoxacin and comparator compounds for 480
bacterial clinical isolates are summarized in Table 1. Clinaﬂoxacin
demonstrated strong activity against all tested bovine and swine
isolates with MIC90 values lower for all isolate groups compared to
danoﬂoxacin and enroﬂoxacin (MIC90 values bovine P. multocida,
M. haemolytica, H. somni, and M. bovis were 0.125, 0.5, 0.125,
and 1 μg/ml, respectively, and the MIC90 values against swine
P. multocida, A. pleuropneumoniae, S. suis, and M. hyopneumo-
niae were ≤0.03, ≤0.03, 0.125, and ≤0.008 μg/ml, respectively).
Clinaﬂoxacin was also very active against mycoplasma isolates
recovered from cattle and pigs. Clinaﬂoxacin MICs obtained
against ATCC cultures in this study were similar to what is listed as
acceptable QC parameters in CLSI (formerly National Committee
Table 1 | In vitro MIC determinations of clinafloxacin and comparator
drugs.
Organism
(no. of strains)
Antimicrobial
agent
MIC (μg/ml)
Range 50% 90%
P. multocida (90)a Clinaﬂoxacin 0.003–0.25 0.007 0.125
Danoﬂoxacin 0.007–8 0.03 2
Enroﬂoxacin 0.007–8 0.03 2
M. haemolytica (95)a Clinaﬂoxacin 0.003–0.5 0.007 0.5
Danoﬂoxacin 0.007–16 0.03 16
Enroﬂoxacin 0.007–16 0.03 16
H. somni (97)a Clinaﬂoxacin 0.003–2 0.007 0.125
Danoﬂoxacin 0.03 to >16 0.06 4
Enroﬂoxacin 0.015 to >16 0.03 2
P. multocida (60)b Clinaﬂoxacin 0.015–0.06 0.015 0.015
Danoﬂoxacin 0.015–0.25 0.06 0.125
Enroﬂoxacin 0.015–0.12 0.06 0.06
A. pleuropneumoniae
(50)b
Clinaﬂoxacin 0.015–0.06 0.015 0.015
Danoﬂoxacin 0.015–0.25 0.06 0.125
Enroﬂoxacin 0.015–0.12 0.015 0.06
S. suis (50)b Clinaﬂoxacin 0.015–1 0.06 0.125
Danoﬂoxacin 0.25–8 0.5 1
Enroﬂoxacin 0.125–4 0.5 1
M. bovis (10)a Clinaﬂoxacin 0.03–1 0.03 1
Danoﬂoxacin 0.125–2 0.5 2
Enroﬂoxacin 0.25 to >8 0.5 >8
M. hyopneumoniae
(18)b
Clinaﬂoxacin ≤0.008 ≤0.008 ≤0.008
Danoﬂoxacin 0.015–0.03 0.03 0.03
Enroﬂoxacin 0.03–0.06 0.06 0.06
M. bovirhinis (10)a Clinaﬂoxacin 0.008–0.03 0.008 0.03
Danoﬂoxacin 0.125 0.125 0.125
Enroﬂoxacin 0.125–0.25 0.125 0.25
aBovine isolates; bswine isolates.
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for Clinical Laboratory Standards, NCCLS; CLSI, 2005; data not
shown).
TIME-KILL ASSAYS
The results of the time-kill kinetic studies are summarized in
Table 2 when tested at drug concentrations that were four times
the MIC. The data are presented in terms of the log CFU change
in which cidality is deﬁned as a ≥3.0 log CFU reduction in the
initial inoculum at 24 h. All of the test agents produced a simi-
lar degree of killing (reduction of 3.8–5.0 log CFU/ml) and were
deﬁned as being cidal. The greatest decrease in CFUs occurred
between 2 and 6 h for all compounds (data not shown). Cli-
naﬂoxacin had a log decrease range of 4.4–5.0 against all organisms
tested.
MPC DETERMINATIONS
Determination of MPC/MIC ratios was determined for test com-
pounds using one strain of S. suis and P. multocida (Table 3). For
clinaﬂoxacin and S. suis, the parent MIC shifted from 0.125 to
0.25 μg/ml for a MPC/MIC ratio of 2 whereas the MIC did not
shift with P. multocida resulting in a ratio of 1. MPC/MIC ratios
using S. suis were 16 and 8 for danoﬂoxacin and enroﬂoxacin,
respectively; using P. multocida the ratio was 4 for danoﬂoxacin
and enroﬂoxacin.
MOUSE EFFICACY ASSAYS
Clinaﬂoxacin and comparator compounds were efﬁcacious with
low ED50 values when tested against livestock pathogens in mouse
IP or IN models (Table 4). ED50 values for clinaﬂoxacin were
determined when dosed three times at 1, 24, and 48 h and 1 and
3 h after an IP challenge with a bovine strain of M. haemolyt-
ica (0.019 and 0.008 mg/kg, respectively) while an ED50 value of
Table 2 |Time-kill results for clinafloxacin and comparator drugs
tested at four times the MIC.
Organism Log decrease (increase) at endpoint
for antibiotica
Clina- Dano- Enro- Control
floxacin floxacin floxacin
M. haemolytica ATCC 33396 4.7 4.1 4.0 (2.2)
AHDRCC 39227 4.8 4.2 3.9 (2.3)
AHDRCC 39228 4.8 4.2 4.0 (2.7)
P. multocida ATCC 43137 4.8 4.2 4.0 (2.3)
AHDRCC 39571 (cattle) 4.5 4.6 4.4 (3.3)
AHDRCC 44344 (swine) 4.6 4.4 4.4 (2.7)
H. somni ATCC 700025 4.4 3.8 4.3 (2.9)
AHDRCC 38925 4.6 4.0 4.1 (2.0)
A. pleuropneumoniae
ATCC 27090
4.6 4.0 4.2 (2.3)
AHDRCC 44672 4.8 4.2 4.2 (2.4)
aThe log CFU per milliliter reduction was calculated at 24 h for all cultures.
Table 3 | Mutant prevention concentration determinations of
clinafloxacin and comparator drugs.
Isolate Drug used
for mutant
selection
Parent
MIC
(μg/ml)
MPC
(μg/ml)
MPC/MIC
ratio
S. suis AHDRCC
43581 (swine)
Clinaﬂoxacin 0.125 0.25 2
Danoﬂoxacin 4 64 16
Enroﬂoxacin 1 8 8
P. multocida
AHDRCC 44349
(bovine)
Clinaﬂoxacin 0.015 0.015 1
Danoﬂoxacin 0.015 0.06 4
Enroﬂoxacin 0.015 0.06 4
0.55 mg/kg was obtained when bovine P. multocida was admin-
istered intranasally and 0.08 mg/kg when administered intraperi-
toneally. The ED50 value was slightly higher at 0.7 mg/kg with the
IP A. pleuropneumoniae model. No evidence of hypoglycemia or
photosensitivity was observed in any mice during these efﬁcacy
studies.
DISCUSSION
The ﬂuoroquinolone antimicrobial agents danoﬂoxacin, enroﬂox
acin, and marboﬂoxacin are currently approved for the treat-
ment of BRD and SRD caused by speciﬁc bacterial respiratory
pathogens. Bacterial resistance is of increasing importance in live-
stock respiratory diseases while the greatest threat to successful
infectious disease treatment and the impetus behind the search for
new antibiotics and other treatment modalities are the evolution
and spread of antibiotic resistance.
Pan and Fisher (1998) investigated the response of S. pneu-
moniae to clinaﬂoxacin and reported that mutations in neither
gyrA nor parC alone had much effect on activity. In that study, it
was determined that high-level resistance to clinaﬂoxacin required
four steps to increase MICs from 0.25 to 64 μg/ml and that the
four steps to resistance involved sequential mutations in gyrA or
gyrB, in parC, in gyrA and ﬁnally in parC or parE. The dual tar-
geting of DNA gyrase and topoisomerase IV and the intrinsic
potency of clinaﬂoxacin are desirable features in limiting the emer-
gence of bacterial resistance (Piddock, 1994; Jones et al., 1999).
Because of clinaﬂoxacin’s unique mechanism of action and its
potential to contribute little to the increase and spread of resis-
tant bacteria, this ﬂuoroquinolone antimicrobial was investigated
as a potential alternative antibacterial agent for respiratory dis-
ease in livestock animals by determining the in vitro activity and
rodent efﬁcacy when tested against pathogens associated with
BRD and SRD.
A recent article by Portis et al. (2012) showed that the in vitro
susceptibility of M. haemolytica respiratory pathogens from 2004
to 2009 has decreased from 89 to 81% with danoﬂoxacin and 95 to
80% with enroﬂoxacin while the in vitro susceptibility of P. mul-
tocida and H. somni respiratory pathogens decreased from 100 to
91 and 100 to 86.2%, respectively, with enroﬂoxacin. However, an
earlier article by Meunier et al. (2004) showed that marboﬂoxacin
was active against 95.4% of bovine pathogenic respiratory strains
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy June 2013 | Volume 4 | Article 154 | 4
“fmicb-04-00154” — 2013/6/12 — 19:21 — page 5 — #5
Sweeney et al. Clinaﬂoxacin for livestock infections
Table 4 | Murine drug efficacy assays.
In vivo model (route of infection) Drugs dosed at: Mean ED50 value (mg/kg/dose)
Ceftiofur (n) Clinafloxacin (n) Enrofloxacin (n)
Bovine M. haemolytica (IP) 1, 24, and 48 h post-challenge 0.28 (5) 0.019 (5) 0.29 (5)
1 and 3 h post-challenge 0.22 (2) 0.008 (2) na
Bovine P. multocida (IN) 18 h post-challenge 1.05 (2) 0. 55 (2) na
Bovine P. multocida (IP) 1 and 3 h post-challenge 0.11 (3) 0.08 (3) 0.26 (3)
Swine A. pleuropneumoniae (IP) 1, 24, and 48 h post-challenge 8.2 (3) 0.7 (3) 1.8 (3)
IP, intraperitoneal; IN, intranasal; n, number of tests; na, not available.
at the end of a 7-year surveillance period. Numerous articles have
attributed decreasing ﬂuoroquinolone susceptibilities to transfer-
able plasmids, mutations in gyrA, gyrB, parC, and parE, and efﬂux
as mechanisms of ﬂuoroquinolone resistance (Martinez-Martinez
et al., 1998; Jones et al., 2000; Alvarez et al., 2008). The data pre-
sented in this study show that MIC90 values for clinaﬂoxacin are
lower for all relevant pathogenic species versus currently marketed
animal health ﬂuoroquinolones used to treat livestock infections.
Additionally, this study showed that clinaﬂoxacin cidality is sim-
ilar to existing ﬂuoroquinolones used to treat livestock infections
and has a better MPC/MIC ratio proﬁle.
The MIC data and the unique equipotent dual mechanism
of action suggest that development of bacterial resistance for
clinaﬂoxacin could be low. This study did not investigate the
mechanism of action of clinaﬂoxacin in livestock pathogens, espe-
cially the Gram-negative organisms which are the prominent
organisms found in livestock respiratory disease. However, it was
reported by Piddock et al. (1998) that none of the newer ﬂuoro-
quinolones tested during the study, except for clinaﬂoxacin with
its dualmechanismof action, had improved activities compared to
ciproﬂoxacin for the Gram-negative P. aeruginosa and H. inﬂuen-
zae isolates. In that study, all second-step mutants, except for
clinaﬂoxacin, required 2 μg/ml or more of a ﬂuoroquinolone for
inhibition (Piddock et al., 1998).
In vitro and in vivo results from this study suggest the poten-
tial of clinaﬂoxacin as a treatment option for livestock respiratory
infections caused by a variety of frequently encountered bacterial
species. Clinaﬂoxacin shows good in vitro activity and efﬁcacy in
mouse models and may be a novel alternative for the treatment
of respiratory disease in cattle and pigs with a potential for low
resistance development. Further developmental studies with this
ﬂuoroquinolone are warranted.
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